不眠症治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 22

2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 32
3.2 Classification 33
3.3 Symptoms 36
3.4 Prognosis 37

4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 38
4.3 Global Trends 39
4.4 Forecast Methodology 41
4.4.1 Sources Used 47
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods 49
4.5 Epidemiological Forecast for Acute Insomnia (2013-2023) 58
4.5.1 Total Prevalent Cases of Acute Insomnia 58
4.5.2 Age-Specific Total Prevalent Cases of Acute Insomnia 60
4.5.3 Sex-Specific Total Prevalent Cases of Acute Insomnia 61
4.5.4 Age-Standardized Total Prevalence of Acute Insomnia 63
4.6 Epidemiological Forecast for Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (2013-2023) 64
4.6.1 Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 64
4.6.2 Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 65
4.6.3 Sex-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 67
4.6.4 Age-Standardized Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 69
4.7 Epidemiological Forecast for Chronic Primary Insomnia (2013-2023) 70
4.7.1 Total Prevalent Cases of Chronic Primary Insomnia 70
4.7.2 Age-Specific Total Prevalent Cases of Chronic Primary Insomnia 71
4.7.3 Sex-Specific Total Prevalent Cases of Chronic Primary Insomnia 73
4.7.4 Age-Standardized Total Prevalence of Chronic Primary Insomnia 75
4.8 Epidemiological Forecast for Chronic Secondary Insomnia (2013-2023) 76
4.8.1 Total Prevalent Cases of Chronic Secondary Insomnia 76
4.8.2 Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia 77
4.8.3 Sex-Specific Total Prevalent Cases of Chronic Secondary Insomnia 79
4.8.4 Age-Standardized Total Prevalence of Chronic Secondary Insomnia 81
4.9 Discussion 82
4.9.1 Epidemiological Forecast Insight 82
4.9.2 Limitations of the Analysis 83
4.9.3 Strengths of the Analysis 84

5 Disease Management 85
5.1 Diagnosis and Treatment Overview 85
5.1.1 Clinical Evaluation 85
5.1.2 Referral 89
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 89
5.1.4 Clinical Practice 91
5.2 US 95
5.3 France 99
5.4 Germany 102
5.5 Italy 104
5.6 Spain 108
5.7 UK 111
5.8 Japan 113

6 Competitive Assessment 117
6.1 Overview 117
6.2 Product Profiles — Major Brands 120
6.2.1 Nonbenzodiazepines 120
6.2.2 Benzodiazepines 158
6.2.3 Melatonin Receptor Agonists 163
6.2.4 Low-Dose Sedating Antidepressants 182
6.2.5 Orexin Receptor Antagonists 195
6.3 Other Therapeutic Classes 206

7 Unmet Need and Opportunity 207
7.1 Overview 207
7.2 Novel Drugs with Improved Safety Profiles 208
7.2.1 Unmet Need 208
7.2.2 Gap Analysis 210
7.2.3 Opportunity 211
7.3 Drugs That Can Be Used for Long-Term Treatment 211
7.3.1 Unmet Need 211
7.3.2 Gap Analysis 212
7.3.3 Opportunity 213
7.4 Availability of Cognitive Behavioral Therapy 213
7.4.1 Unmet Need 213
7.4.2 Gap Analysis 215
7.4.3 Opportunity 215
7.5 Drugs That Improve the Quality of Sleep 216
7.5.1 Unmet Need 216
7.5.2 Gap Analysis 217
7.5.3 Opportunity 218
7.6 Education for Primary Care Physicians 218
7.6.1 Unmet Need 218
7.6.2 Gap Analysis 219
7.6.3 Opportunity 220

8 Pipeline Assessment 221
8.1 Overview 221
8.2 Clinical Trial Mapping 221
8.2.1 Clinical Trials by Sponsor Type 221
8.3 Promising Drugs in Clinical Development 222
8.3.1 E-2006 223
8.3.2 Piromelatine 228
8.4 Promising Drugs in Early-Stage Development 233
8.5 Other Drugs in Development 235

9 Current and Future Players 236
9.1 Overview 236
9.2 Trends in Corporate Strategy 240
9.3 Company Profiles 242
9.3.1 Sanofi 242
9.3.2 Sunovion/Dainippon Sumitomo 245
9.3.3 Pfizer 247
9.3.4 Takeda 251
9.3.5 Merck & Co. 254
9.3.6 Meda 258
9.3.7 Eisai 261
9.3.8 Purdue 263
9.3.9 Neurim 266
9.3.10 Pernix Therapeutics 270

10 Market Outlook 273
10.1 Global Markets 273
10.1.1 Forecast 273
10.1.2 Drivers and Barriers — Global Issues 277
10.2 United States 279
10.2.1 Forecast 279
10.2.2 Key Events 282
10.2.3 Drivers and Barriers 282
10.3 France 284
10.3.1 Forecast 284
10.3.2 Key Events 287
10.3.3 Drivers and Barriers 287
10.4 Germany 289
10.4.1 Forecast 289
10.4.2 Key Events 292
10.4.3 Drivers and Barriers 292
10.5 Italy 294
10.5.1 Forecast 294
10.5.2 Key Events 297
10.5.3 Drivers and Barriers 297
10.6 Spain 298
10.6.1 Forecast 298
10.6.2 Key Events 302
10.6.3 Drivers and Barriers 302
10.7 United Kingdom 304
10.7.1 Forecast 304
10.7.2 Key Events 307
10.7.3 Drivers and Barriers 307
10.8 Japan 309
10.8.1 Forecast 309
10.8.2 Key Events 312
10.8.3 Drivers and Barriers 312

11 Appendix 314
11.1 Bibliography 314
11.2 Abbreviations 348
11.3 Methodology 352
11.4 Forecasting Methodology 352
11.4.1 Diagnosed Insomnia Patients 352
11.4.2 Percent Drug-Treated Patients 353
11.4.3 Drugs Included in Each Therapeutic Class 353
11.4.4 Launch and Patent Expiry Dates 354
11.4.5 General Pricing Assumptions 355
11.4.6 Individual Drug Assumptions 356
11.4.7 Generic Erosion 369
11.4.8 Pricing of Pipeline Agents 370
11.5 Primary Research — KOLs Interviewed for this Report 371
11.6 Primary Research — Prescriber Survey 373
11.7 About the Authors 374
11.7.1 Analyst 374
11.7.2 Therapy Area Director 374
11.7.3 Epidemiologist 375
11.7.4 Global Head of Healthcare 375
11.8 About GlobalData 376
11.9 Disclaimer 376


【レポート販売概要】

■ タイトル:不眠症治療薬の世界市場予測および分析
■ 英文:PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年2月27日
■ 調査会社:GlobalData
■ 商品コード:GDHC107PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。